We have shown that adenoviral vector mediated delivery of the p19Arf and IFNβ (p19Arf/IFNβ) combination to tumor cells that harbor wild type p53, such as B16F10, unleashes a cell death program that displays features of necroptosis, while mediating the release of bona fide ICD markers as well as immune protection against a secondary tumor challenge14–16. Here, TP53 is linked to neoplasm.